Non-clinical development of CER-001

por Barbaras, Ronald
Publicado 2015

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings

por Keyserling, Constance H., Barbaras, Ronald, Benghozi, Renee, Dasseux, Jean-Louis
Publicado 2017

P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo

por Goffinet, Marine, Tardy, Claudine, Boubekeur, Nadia, Cholez, Guy, Bluteau, Alice, Oniciu, Daniela C., Lalwani, Narendra D., Dasseux, Jean-Louis H., Barbaras, Ronald, Baron, Rudi
Publicado 2014

HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE(-/-) Mice: Evidence of ABCA1 Down-Regulation

por Tardy, Claudine, Goffinet, Marine, Boubekeur, Nadia, Cholez, Guy, Ackermann, Rose, Sy, Gavin, Keyserling, Constance, Lalwani, Narendra, Paolini, John F., Dasseux, Jean-Louis, Barbaras, Ronald, Baron, Rudi
Publicado 2015

Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project

por Stasi, Alessandra, Fiorentino, Marco, Franzin, Rossana, Staffieri, Francesco, Carparelli, Sabrina, Losapio, Rosa, Crovace, Alberto, Lacitignola, Luca, Cimmarusti, Maria Teresa, Murgolo, Francesco, Stufano, Monica, Cafiero, Cesira, Castellano, Giuseppe, Sallustio, Fabio, Ferrari, Chiara, Ribezzi, Mario, Brienza, Nicola, Schirinzi, Annalisa, Di Serio, Francesca, Grasso, Salvatore, Pontrelli, Paola, Tupin, Cyrille, Barbaras, Ronald, Keyserling-Peyrottes, Constance, Crovace, Antonio, Gesualdo, Loreto
Publicado 2023